
Haemonetics (HAE) Stock Forecast & Price Target
Haemonetics (HAE) Analyst Ratings
Bulls say
Haemonetics is expected to continue growing in their core Plasma segment, has a Buy rating and $96 price target, and recently received FDA approvals for new products. They are undergoing a restructuring and have two main business units, Apheresis and MedSurg, with potential for growth through mergers and acquisitions. However, competition and potential impacts on demand for their products may pose risks to their rating and price target.
Bears say
Haemonetics is facing challenges in meeting their guidance and long-term financial targets due to increased operating spend and potential tariff impacts, leading to a below-midpoint revenue estimate for FY2027. While the company has potential for growth with new products and potential M&A in the high-growth MedTech industry and strong brand reputation, risks such as competition, procedure volumes, and potential treatments could impact demand for their products. Despite potential growth opportunities, the negative outlook is driven by uncertainties and risks that could impact the company's financial performance and hinder its ability to meet its targets.
This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.
Haemonetics (HAE) Analyst Forecast & Price Prediction
Start investing in Haemonetics (HAE)
Order type
Buy in
Order amount
Est. shares
0 shares